Biodesix Inc. (BDSX) Reports In-Line Q4 EPS

Biodesix Inc. (NASDAQ: BDSX) reported Q4 EPS of ($0.49), in-line with the analyst estimate of ($0.49). Revenue for the quarter came in at $7.2 million versus the consensus estimate of $7.3 million.

GUIDANCE:

Biodesix Inc. sees FY2022 revenue of $37.5-39.5 million, versus the consensus of $35.5 million.

For earnings history and earnings-related data on Biodesix Inc. (BDSX) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Boxlight Corporation (BOXL) Tops Q2 EPS by 2050c
• Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation